Evidence map›Paper›PMID 42258104›Full record

ArticlePhysical and engineering sciences in medicine2026

Complementary roles of GPU-accelerated Monte Carlo and ArcCHECK in TomoTherapy quality assurance.

Panxia Wu, Wenheng Zheng, Longfei Xu, XingXing Yuan, Changfei Gong, Changwei Luo, Junming Jian, Shenggou Ding, Yun Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Physical and engineering sciences in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Panxia WuDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Wenheng ZhengDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Longfei XuDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
XingXing YuanDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Changfei GongDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Changwei LuoDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Junming JianDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China.
Shenggou DingDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China. dsg8334922@163.com.
Yun ZhangDepartment of Radiation Oncology, Jiangxi Cancer Hospital (The Second Affiliated Hospital of Nanchang Medical College), Nanchang, 330029, Jiangxi, China. zhangyun_1983@sohu.com.

Funding

Jiangxi Cancer Hospital & Institute WCDJ2024JQ01
6 · The paper itself

Abstract

The complex dose delivery mechanisms of TomoTherapy (TOMO) demand rigorous patient-specific quality assurance (PSQA). This study systematically evaluates the relationship between ArcCHECK measurements and GPU-accelerated Monte Carlo (GPU-MC) calculations for nasopharyngeal carcinoma (NPC) TOMO plans across multiple gamma criteria, aiming to delineate their respective strengths and inform an optimized verification strategy. A retrospective analysis was conducted on 317 TOMO plans for NPC, each optimized using the Accuray Precision Treatment Planning System. Patient-specific dose verification was performed using ArcCHECK measurements and independent MC calculations implemented through PlanQA. Gamma passing rates (GPRs) were evaluated under nine different conditions, including both same-criterion and cross-criterion comparisons. To assess differences, agreement, and correlations between methods, statistical analyses were conducted using the Wilcoxon signed-rank test, Bland-Altman analysis, and Spearman correlation. Under identical Gamma criteria, there was no statistically significant difference in GPR between ArcCHECK and MC. However, cross-criterion comparisons revealed marked discrepancies, highlighting the criterion-dependent nature of GPR outcomes. Lenient standards typically exhibit good consistency and relatively minor deviations. Furthermore, the correlations among all combinations of these standards can be considered negligible. The comparable performance of GPU-MC and ArcCHECK under conventional criteria (3%/3 mm, 3%/2 mm) validates ArcCHECK's established role in verifying delivery fidelity. Crucially, under the stringent 2%/2 mm criterion where ArcCHECK passing rates decline, MC provides critical diagnostic power to differentiate between discrepancies originating from the dose calculation algorithm and those arising from the physical delivery process. For TOMO PSQA, GPU-MC and ArcCHECK are complementary. An integrated approach leveraging both methods is therefore recommended.

Indexed as

Computer GraphicsMonte Carlo MethodQuality Assurance, Health CareRadiotherapy, Intensity-ModulatedAlgorithmsHumansNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRetrospective StudiesArcCHECKDosimetric verificationGamma evaluation criteriaMonte CarloNasopharyngeal carcinomaTomoTherapy

Identifiers

PMID42258104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.